- Corporate
Basilea Pharmaceutica Ltd. is a commercial stage biopharmaceutical company developing products that address the medical challenge of increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. Basilea is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions.
News
Basel, Switzerland, September 12, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Basilea Pharmaceutica International Ltd. (Basilea) has entered into a distribution agreement with Cardiome Pharma Corp. (Cardiome; NASDAQ: CRME, TSX: COM) for Basilea's antibiotic Zevtera®/Mabelio® (ceftobiprole) in Europe (excluding Nordic countries) and Israel.
more...
- Completed license agreement with Pfizer for Cresemba in Europe (excluding Nordics), Russia, Turkey and Israel; CHF 70 million upfront payment and up to USD 427 million in milestones
- 56 percent increase in total revenue, amounting to CHF 46.2 million
- BARDA committed USD 54.8 million in additional funding to support phase 3 development of ceftobiprole for registration in the U.S.
- Agreement with Adult Brain Tumor Consortium for phase 1 clinical study to explore BAL101553 in newly diagnosed glioblastoma
more...
Basel, Switzerland, July 20, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that its license agreement with Pfizer Inc. (NYSE: PFE) for Basilea's antifungal Cresemba (isavuconazole), which was announced on June 14, has completed and therefore will now be implemented.
more...
- Basilea receives a CHF 70 million upfront payment and is eligible for additional milestone payments of up to USD 427 million and double-digit royalties on sales
- Basilea continues to focus on establishing further partnerships for the commercialization of its anti-infectives Cresemba and Zevtera in key markets around the world
- Basilea explores partnering opportunities to further strengthen its anti-infectives and oncology R&D portfolio
more...
© 2017 Basilea Pharmaceutica Ltd.
